Homing peptides for systemic targeting: discovery and applications in cancer...
Highlights
stay up to date
Latest News
Updates on our activities
working on the following programs
PATHOLOGIES
PATHOLOGIES
upcoming events
Save the date!
November
Event Details
Monitoring tumor evolution and drug resistance through a novel circulating tumor extracellular vesicle-based liquid biopsy Speaker: Dr. Irene Casanova Salas Institution: Prostate Cancer Translational Research Team. Vall Hebron Institute of Oncology
Event Details
Monitoring tumor evolution and drug resistance through a novel circulating tumor extracellular vesicle-based liquid biopsy
Speaker: Dr. Irene Casanova Salas
Institution: Prostate Cancer Translational Research Team. Vall Hebron Institute of Oncology (VHIO). Barcelona, Spain.
Place: Jerónimo Forteza conference room, CIPF
Abstract: Understanding the mechanisms underlying therapy resistance and heterogeneity in metastatic prostate cancer (mPC) is essential for developing more effective treatment strategies. Traditional biopsy methods for studying drug resistance are limited by their invasiveness and inability to capture dynamic changes over time. Moreover, single-biopsy analyses may fail to fully represent the complexity of tumor evolution. Liquid biopsies, which analyze blood samples, offer a minimally invasive approach for longitudinal monitoring of cancer dynamics. Current methods primarily focus on next-generation sequencing (NGS) analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), tracking tumor-specific changes throughout disease progression. However, other sources, such as extracellular vesicles (EVs)—small particles released by tumor cells into circulation—contain stable DNA and RNA, providing a novel means to monitor genomic and transcriptomic changes. Our RExCuE (mRNA Expression in Circulating EVs) platform exemplifies this capability, offering an innovative tool for monitoring mRNA alterations in circulation.
Profiling circulating tumor EVs enables a deeper understanding of the adaptive responses of tumors and their ecosystems to treatment, ultimately supporting more effective and personalized therapeutic strategies
PATROCINADO POR:
With support from the Generalitat Valenciana, AMPER-07/2024 and CIAORG/2023/147
Time
25.11.2024 12:30 - 13:30(GMT+01:00)
Location
Centro de Investigación Príncipe Felipe
Eduardo Primo Yúfera, 3 Valencia Spain
December
Event Details
Event Details
Time
09.09.2024 15:00 - 22.11.2024 18:00(GMT+01:00)
Location
Centro de Investigación Príncipe Felipe
Eduardo Primo Yúfera, 3 Valencia Spain
Event Details
Event Details
Time
14.10.2024 15:00 - 13.12.2024 18:00(GMT+01:00)
Location
Centro de Investigación Príncipe Felipe
Eduardo Primo Yúfera, 3 Valencia Spain
Event Details
Monitoring tumor evolution and drug resistance through a novel circulating tumor extracellular vesicle-based liquid biopsy Speaker: Dr. Irene Casanova Salas Institution: Prostate Cancer Translational Research Team. Vall Hebron Institute of Oncology
Event Details
Monitoring tumor evolution and drug resistance through a novel circulating tumor extracellular vesicle-based liquid biopsy
Speaker: Dr. Irene Casanova Salas
Institution: Prostate Cancer Translational Research Team. Vall Hebron Institute of Oncology (VHIO). Barcelona, Spain.
Place: Jerónimo Forteza conference room, CIPF
Abstract: Understanding the mechanisms underlying therapy resistance and heterogeneity in metastatic prostate cancer (mPC) is essential for developing more effective treatment strategies. Traditional biopsy methods for studying drug resistance are limited by their invasiveness and inability to capture dynamic changes over time. Moreover, single-biopsy analyses may fail to fully represent the complexity of tumor evolution. Liquid biopsies, which analyze blood samples, offer a minimally invasive approach for longitudinal monitoring of cancer dynamics. Current methods primarily focus on next-generation sequencing (NGS) analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), tracking tumor-specific changes throughout disease progression. However, other sources, such as extracellular vesicles (EVs)—small particles released by tumor cells into circulation—contain stable DNA and RNA, providing a novel means to monitor genomic and transcriptomic changes. Our RExCuE (mRNA Expression in Circulating EVs) platform exemplifies this capability, offering an innovative tool for monitoring mRNA alterations in circulation.
Profiling circulating tumor EVs enables a deeper understanding of the adaptive responses of tumors and their ecosystems to treatment, ultimately supporting more effective and personalized therapeutic strategies
PATROCINADO POR:
With support from the Generalitat Valenciana, AMPER-07/2024 and CIAORG/2023/147
Time
25.11.2024 12:30 - 13:30(GMT+01:00)
Location
Centro de Investigación Príncipe Felipe
Eduardo Primo Yúfera, 3 Valencia Spain
27nov10:0012:00A Practical Lipidomic Data Analysis SessionBIOINFORMATICS TRAINING COURSES 2024
Event Details
Event Details
Time
27.11.2024 10:00 - 12:00(GMT+01:00)
Location
Centro de Investigación Príncipe Felipe
Eduardo Primo Yúfera, 3 Valencia Spain
lectures
SHARING knowledge
DISCOVER
meet our scientists
NEURODEGENERATIVE DISORDERS
CANCER AND INFLAMMATION
AND REGERENATIVE MEDICINE
MIGRATION AND CANCER INVASION
BIOENGINEERING
HOST-MICROBIOME INTERACTIONS